文献速递免疫规划卫生政策与健康促进

加拿大免疫研究网络研究:新冠疫苗接种后疑似超敏反应青少年和成人的再接种结局

Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study.
PubMed 文献 · Vaccine · 2024-06-22

加拿大特殊免疫接种门诊网络纳入206名12岁及以上、因新冠疫苗接种后疑似或确诊超敏反应或接种前评估转诊者,应用2023版Brighton协作组过敏反应病例定义评估。180名接种后不良事件转诊者中,166/180(92.2%)经风险评估推荐再接种,158/166(95.2%)实际再接种,再接种后过敏反应复发比例低。

要点

  • 180名接种后不良事件转诊者中,15/180(8.3%)为Brighton协作组确诊过敏反应。
  • 166/180(92.2%)经风险评估推荐再接种,158/166(95.2%)实际再接种,均使用新冠mRNA疫苗。
  • 再接种后符合Brighton协作组过敏反应标准的复发:既往过敏反应者1/15(6.7%),未达过敏反应标准的速发型超敏反应者1/77(1.3%),其他医生诊断超敏反应者1/24(4.2%)。

核心结论

  • 该全国队列中多数新冠疫苗接种后发生超敏反应并转诊专科评估者再接种后未复发不良事件,提示专科评估可促进安全再接种。

研究设计与样本

  • 加拿大特殊免疫接种门诊网络研究,纳入2023年2月28日前入组、12岁及以上因新冠疫苗接种后疑似或确诊超敏反应或接种前评估转诊者,分析集中数据库中的临床评估与再接种数据,应用2023版Brighton协作组过敏反应病例定义。

主要发现

  • 分析纳入13个中心的206名参与者:26名接种前评估转诊,180名接种后不良事件转诊。
  • 180名接种后不良事件转诊者中,15/180(8.3%)为Brighton协作组确诊过敏反应,84名(46.7%)为不符合Brighton协作组标准的速发型超敏反应症状,33名(18.3%)为其他诊断的超敏反应,48名(26.7%)最终诊断为非超敏性不良事件。
  • 180名接种后不良事件转诊者中,166/180(92.2%)经风险评估推荐再接种,其中158/166(95.2%)再接种,均使用新冠mRNA疫苗。
  • 再接种后符合Brighton协作组过敏反应标准的复发不良事件症状:既往过敏反应者1/15(6.7%),不符合过敏反应标准的速发型超敏反应者1/77(1.3%),其他医生诊断超敏反应者1/24(4.2%)。
  • 26名接种前评估转诊者(包括9名(34.6%)有聚乙二醇-门冬酰胺酶反应史)接种后均未发生速发型超敏反应症状。

临床怎么用

  • 作者认为专科评估可促进新冠疫苗接种后发生超敏反应者的安全再接种。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 vaccination has been associated with anaphylaxis and hypersensitivity reactions. Infectious disease physicians and allergists in the Canadian Special Immunization Clinic (SIC) Network developed guidance for evaluating patients with adverse events following immunization (AEFI) including suspected hypersensitivity. This study evaluated management and adverse event recurrence following subsequent COVID-19 vaccinations. METHODS: Individuals aged 12 years and older enrolled at participating SICs before February 28, 2023 who were referred for suspected or diagnosed hypersensitivity reaction following COVID-19 vaccination, or for prevaccination assessment of suspected allergy to a COVID-19 vaccine component were included. De-identified clinical assessments and revaccination data, captured in a centralized database, were analyzed. The Brighton Collaboration case definition (BCCD) for anaphylaxis (2023 version) was applied. RESULTS: The analysis included 206 participants from 13 sites: 26 participants referred for pre-vaccination assessment and 180 participants referred for adverse events following COVID-19 vaccination (15/180 [8.3%] with BCCD confirmed anaphylaxis, 84 [46.7%] with immediate hypersensitivity symptoms not meeting BCCD, 33 [18.3%] with other diagnosed hypersensitivity reactions, and 48 [26.7%] participants with a final diagnosis of non-hypersensitivity AEFI). Among participants referred for AEFIs following COVID-19 vaccination, 166/180 (92.2%) were recommended for COVID-19 revaccination after risk assessment, of whom 158/166 (95.2%) were revaccinated (all with a COVID-19 mRNA vaccine). After revaccination, 1/15 (6.7%) participants with prior anaphylaxis, 1/77 (1.3%) with immediate hypersensitivity not meeting criteria for anaphylaxis and 1/24 (4.2%) with other physician diagnosed hypersensitivity developed recurrent AEFI symptoms that met the BCCD for anaphylaxis. All 26 participants referred pre-vaccination, including 9 (34.6%) with history of polyethylene glycol-asparaginase reactions, were vaccinated without occurrence of immediate hypersensitivity symptoms. CONCLUSIONS: Most individuals in this national cohort who experienced a hypersensitivity event following COVID-19 vaccination and were referred for specialist review were revaccinated without AEFI recurrence, suggesting that specialist evaluation can facilitate safe revaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fitzpatrick T, Yamoah P, Lacuesta G, et al. Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study. Vaccine. 2024. PMID: 38910092. doi:10.1016/j.vaccine.2024.06.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。